Beike Biotech

Source: The Hindu     

See Listing on Clinicaltrials.gov. 

NEW DELHI: Fortis Healthcare on Wednesday announced the commencement of a crucial clinical trial that is expected to help in treatment of diabetes.

Hospital Director and Head of the Department of Diabetes and Metabolic Diseases, Dr. Anoop Misra, said the Fortis Hospital at Vasant Kunj would be the forerunner in the clinical trial of stem cell therapy that has been formally approved by the Indian Council of Medical Research. The research would be conducted on patients with diabetic foot ulcers.

Fortis Healthcare has tied up with Beike Biotech India Private Limited for conducting the clinical trial.

The stem cell trial for diabetic foot will start in the first week of July. Thirty-six patients will be enrolled for the study, out of whom 12 will receive stem cell therapy. All 36 patients will undergo extensive and comprehensive tests at regular intervals.

With the prime focus of healing diabetic foot ulcers with stem cells, highly sophisticated tests like nuclear magnetic resonance angiography and peripheral arterial doppler screening would also be conducted along with routine investigations to assess new blood vessel formation. Breaking the barriers of the current treatment available for diabetic foot which is long and expensive, this study is expected to bring new hope.

 May 20, Xiangyang and Shenzhen Beike Biotech Co. Ltd. held a stem cell research and industry promotion cooperation signing ceremony. City leaders Mr. wan and Mr. Huang were in attendance.

 Under the agreement, Beike Biotech Co. Ltd. will set up “Hubei Province Beike Biotech Co. Ltd.” Hubei Beike Biotech will consist of an international-quality research and development laboratory, stem cell research facilities and a stem cell bank. The agreement will integrate domestic and foreign resources for stem cell research, provide technical support on stem cell research and streamline the clinical application of stem cells, serving Xiangfan and nearby hospitals.

 At the completion of the project, Hubei Beike Biotech will strengthen Xiangfan’s biomedical industry and promote economic development in the area as well as enhance public health.

Beike Biotechnology has issued two updates to the past press release: Stem Cell Leader Beike Signs Eight New Cooperation Agreements, Establishes Safety Monitoring Board

An Interview with Sean Hu, of Beike Biotechnology

Source: Hplusmagazine

By Karolyn Y. Zeng

President Obama’s recent U.S. stem cell policy reversal allows federally funded researchers to use hundreds of new embryonic stem cell lines. "Our government has forced what I believe is a false choice between sound science and moral values," Obama declared as he signed documents changing U.S. science policy in March 2009.The U.S. is a bit late to the global stem cell research game. Japan’s Dr. Shinya Yamanaka demonstrated the ability to reprogram adult cells to behave as embryonic stem cells as early as 2007. But it is in China’s Guangdong Province that there have been almost miraculous strides in actually using stem cells to treat and cure diseases such as blindness, cerebral palsy, and spinal cord injuries.

Dr. Sean Hu is a soft-spoken powerhouse of a man who holds both an M.D. from China and a Ph.D. in Biochemistry and Molecular Biology from Gothenburg University in Sweden. The company he founded, Beike (bei-ker) Biotechnology, is one of the leading players in stem cell therapy. Headquartered in Shenzhen – not far from Hong Kong – Beike has become a therapeutic refuge for a fast-growing number of patients seeking stem cell treatments.